Stürner, Klarissa Hanja http://orcid.org/0000-0003-2199-3315
Werz, Oliver http://orcid.org/0000-0002-5064-4379
Koeberle, Andreas http://orcid.org/0000-0001-6269-5088
Otto, Markus http://orcid.org/0000-0003-4273-4267
Pless, Ole http://orcid.org/0000-0002-1468-316X
Leypoldt, Frank
Paul, Friedemann
Heesen, Christoph
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (0315610-0315620-0315620, 16GW0082, 0315610-0315620)
Article History
Received: 6 December 2019
Accepted: 29 April 2020
First Online: 29 May 2020
Competing interests
: Klarissa Hanja Stürner has received personal fees and travel grants from Bayer, Biogen, MerckSerono and Genzyme during the last 5 years. F. Leypoldt reports speaker honoraria from Bayer, Roche, Novartis, Fresenius, travel funding from Merck, Grifols and Bayer and serving on advisory boards for Roche, Biogen and Alexion. Friedemann Paul has received honoraria and research support from Alexion, Bayer, Biogen, Chugai, MerckSerono, Novartis, Genzyme, MedImmune, Shire, Teva, and serves on scientific advisory boards for Alexion, MedImmune and Novartis. He has received funding from Deutsche Forschungsgemeinschaft (DFG Exc 257), Bundesministerium für Bildung und Forschung (Competence Network Multiple Sclerosis), Guthy Jackson Charitable Foundation, EU Framework Program 7, National Multiple Sclerosis Society of the USA. Ole Pless, Oliver Werz and Andreas Koeberle have nothing to disclose and declare no potential conflict of interest. Markus Otto served as consultant for Biogen, Roche, Axon Neuroscience and Fujirebio. C. Heesen has received travel and research grants from Biogen, Genzyme, Merck, Novartis and Roche.